Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 157Carcinoma, Intraductal, Noninfiltrating 16Breast Carcinoma In Situ 12Neoplasm Metastasis 9Ovarian Neoplasms 7Breast Neoplasms, Male 7Neoplasms 4Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Glioblastoma 3Breast Cancer Female 3Urinary Bladder Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Obesity 2Infertility 2Hot Flashes 2Fibroadenoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2ER+ Breast Cancer 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Wake Disorders 1Sexuality 1Risk Reduction Behavior 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Primary Breast Cancer 1

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HR Positive HER2 Negative Advanced Breast Cancer × Tamoxifen × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡